Sound Bioventures

Artax Biopharma validates AX-158, a first-in-class oral Nck modulator, in phase 2a for autoimmune disease

AnaCardio secures USD 19 million to advance AC01 development for heart failure and reports positive result from Phase 1b study 💲 USD 19 million financing round closed with new international investors Novo Holdings, Pureos Bioventures and Sound Bioventures 💊 AC01, a selective oral ghrelin receptor (GHSR1a) agonist was well tolerated in patients with chronic, stable HFrEF 🫀 Clear target engagement demonstrated and exploratory pharmacodynamic measurements indicated increased contractility Read more about this exciting milestone and our Phase 1b results here: https://lnkd.in/dwKp2XXH #HeartFailure #Funding #Biotech #Innovation #Healthcare #AnaCardio

Life Sciences ESG Knowledge Project releases its 2025 benchmark questionnaire for investors. With 23 Life Science investors participating, the Knowledge Project aims to coordinate approaches on ESG within the European Life Science investment community. The Knowledge Project has released its 2025 questionnaire for investors to use and is now freely available to download on our website: https://brnw.ch/21wOPNl 𝐂𝐨𝐨𝐫𝐝𝐢𝐧𝐚𝐭𝐞𝐝 𝐚𝐩𝐩𝐫𝐨𝐚𝐜𝐡 𝐭𝐨 𝐄𝐒𝐆 𝐝𝐚𝐭𝐚 𝐜𝐨𝐥𝐥𝐞𝐜𝐭𝐢𝐨𝐧 The questionnaire was first built in 2023 to cover the material ESG matters for the Life Science investment industry, aligning to existing industry questionnaires and other disclosure guiding standards, such as the Sustainable Financial Disclosure Regulation (SFDR) and the European Sustainability Reporting Standards (ESRS). The 2025 Questionnaire has been updated to consider the latest developments in ESG for the industry, and reviewed to ensure it is fit for purpose for both portfolio companies and investors. 𝐎𝐩𝐞𝐧 𝐟𝐨𝐫 𝐧𝐞𝐰 𝐩𝐚𝐫𝐭𝐢𝐜𝐢𝐩𝐚𝐧𝐭𝐬 The Knowledge Project remains open to new participants joining as fee-paying members, which enables access to benchmarking data, contribution to questionnaire development as well as other knowledge sharing and industry events. If you are interested in joining the project, discussing how we can support investors on ESG and Impact or in exploring a similar collaboration for your industry, please contact Jason Feldman or Tom van Mierlo. #ESG #venturecapital #investors #socialresponsibility #impacthouse #grantthorntonnetherlands

Today we announce that we have dosed the first patient in our Phase I/IIa trial of THEO-260 in patients with advanced-stage platinum-resistant ovarian cancer. THEO-260 is uniquely positioned to tackle the complex, immune supressed nature of advanced solid tumours.   This is a major milestone for Theolytics and brings us closer to delivering effective new treatment options for the many women who suffer from ovarian cancer, one of the leading causes of cancer-related deaths among women.   Read the full announcement: https://lnkd.in/ew26JC_B #OvarianCancer #ImmunoOncology #OncolyticImmunotherapy  

VarmX announces appointment of John Glasspool as CEO Leadership team fully strengthened to drive next phase of development We’re pleased to welcome international life sciences industry veteran John Glasspool as CEO of VarmX.    He brings over 30 years’ experience within the global biopharma industry, linking science and business. His expertise includes building and growing companies, fundraising and investing, licensing, partnering and commercialisation.    Jan Øhrstrøm, Chairman of VarmX, commented: “John’s knowledge of the coagulation and urgent care therapeutics space will be invaluable as we take VMX-C001 forward. Our leadership team is now significantly strengthened to enable us to drive the next stage of our growth with a Series C fundraise and a pivotal clinical trial.” See the news here: https://lnkd.in/dBFM3JrU #management #appointment #lifesciences #innovation +44 20 7390 0230 VarmX@vigoconsulting.com